Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 99, Issue 11, 2005, Pages 1418-1424

  John, Matthias ^a   Bosse, Susanne ^a   Oltmanns, Ute ^a   Schumacher, Axel ^a   Witt, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

COPD; Cytokines; HFA 134 beclomethason; Inhaled corticosteroids; Quality of life

Indexed keywords

BECLOMETASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; VENTOLAIR;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPIRATORY FLOW; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; LUNG FUNCTION; LUNG INFLATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT COURSE THERAPY; SYMPTOMATOLOGY; TOTAL LUNG CAPACITY;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LUNG; MALE; MIDDLE AGED; MONOCYTES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 27144453619     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.03.034     Document Type: Article

References (18)

1. S. Spencer P.M. Calverley B.P. Sherwood P.W. Jones Health status deterioration in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 122-128
2. P.J. Barnes Chronic obstructive pulmonary disease N Engl J Med 343 2000 269-280
3. P. van der Valk E. Monninkhof J. van der Palen G. Zielhuis C. van Herwaarden Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 166 2002 1358-1363
4. The Lung Health Study Research Group Effect of inhaled triamchinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902-1909
5. P.S. Burge P.M. Calverley P.W. Jones S. Spencer J.A. Anderson T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial Br Med J 320 2000 1297-1303
6. J. Bourbeau M.Y. Rouleau S. Boucher Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease Thorax 53 1998 477-482
7. R.A. Pauwels C.G. Lofdahl L.A. Laitinen J.P. Schouten D.S. Postma N.B. Pride S.V. Ohlsson Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease N Engl J Med 340 1999 1948-1953
8. J. Vestbo Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial Lancet 353 1999 1819-1823
9. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and Readmission in elderly patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
10. B.R. Celli W. MacNee Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur Respir J 23 2004 932-946
11. R.A. Pauwels A.S. Buist P.M. Calverley C.R. Jenkins S.S. Hurd Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease GOLD) Workshop Summary Am J Respir Crit Care Med 163 2001 1256-1276 update 2004: http://www.goldcopd.com
12. P.W. Jones F.H. Quirk C.M. Baveystock P. Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321-1327
13. P.W. Jones Health status measurement in chronic obstructive pulmonary disease Thorax 56 2001 880-887
14. P.W. Jones F.H. Quirk C.M. Baveystock P. Littlejohns A self-complete measure for pirchronic airflow limitation- the St. George's Respiratory Questionnaire Am Rev Respir Dis 1992 1321-1327
15. M. John S. Lim et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1 α, granulocyte-macrophage colony-stimulating factor, and interferon- γ release from alveolar macrophages in asthma Am J Respir Crit Care Med 157 1998 256-262
16. P.J. Barnes New therapies for chronic obstructive pulmonary disease Thorax 53 1998 137-147
17. P.J. Barnes Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 342-344
18. W.E. Kamin T. Genz S. Roeder G. Scheuch T. Trammer R.M. Juenemann Cloes Mass output and particle size distribution of glucocorticosteroids from different inhalation devices depending on vario inspiratory parameters J Aerosol Med 15 1 2002 65-73